Hydroxyurea, a modifying therapy for sickle cell is expected to be provided under the National Health Insurance Scheme (NHIS).
The move, according to Vice President Dr Mahamudu Bawumia, is to help improve the physical health of people living with sickle cell in Ghana.
“This is a promise that has been fulfilled by President Nana Addo Dankwa Akufo-Addo,” he said in a post on Facebook.
“As the world marked Sickle Cell Awareness Day on 19th June, I am pleased to announce that at a meeting I chaired on June 8, 2021, with stakeholders including Professor Ohene Frimpong, President of the Sickle Cell Foundation, the Minister of Health, the National Health Insurance Authority and Novartis, it was agreed that hydroxyurea, a modifying therapy for sickle cell will now be provided under the NHIS to improve the physical health of people living with it.“
By Melvin Tarlue